Home > Pulmonology > Triple therapy provides robust and durable benefits in cystic fibrosis

Triple therapy provides robust and durable benefits in cystic fibrosis


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Respiratory Medicine
Reuters Health - 30/12/2021 - Triple combination therapy with elexacaftor, ivacaftor and tezacaftor has advantages over tezacaftor plus ivacaftor in people with cystic fibrosis (CF) homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene, according to results of a phase-3b trial. "The elexacaftor plus tezacaftor plus ivacaftor regimen was safe and well tolerated, and led to significant and clinically meaningful improvements in respiratory-related quality of life and lung function, as well as improved CFTR function, changes that were durable over 24 weeks and superior to those seen with tezacaftor plus ivacaftor in this patient population," the study team reports in The Lancet Respiratory Medicine. Vertex Pharmaceuticals, which markets the triple-drug combo as Trikafta and the two-drug combo as Symdeco in the U.S., funded the study. The study included 175 patients aged 12 and older with CF and two F508del-CFTR alleles, sta...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on